Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 73

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

Summary

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Cognitive Disorders, Parkinson's Disease, Schizophrenia, Smoking Addiction, Traumatic Brain Injury, Chronic Cough, Chronic Pain, Cognitive Impairment, Complex Regional Pain Syndrome, Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Ischemic Stroke, Major Depressive Disorder, Neurodegenerative Diseases, Neuropathic Pain, Obesity, Pain and Post-Traumatic Stress Disorder (PTSD).

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
Bionomics Ltd
Bristol-Myers Squibb Co
CoMentis Inc
Epigen Biosciences Inc
Johnson & Johnson
Merck & Co Inc
Neuro Bio Ltd
NeuroDerm Ltd
SK Biopharmaceuticals Co Ltd
Vanda Pharmaceuticals Inc
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
(nicotine + opipramol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bradanicline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gln-1062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTS-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-39393406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-20540 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VQW-765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
Featured News & Press Releases
May 23, 2018: Bionomics: Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation
Apr 11, 2018: Phase 2 Clinical Trial of BNC210 For Treatment of Post traumatic Stress Disorder Fully Recruited
Apr 06, 2018: Bionomics To Host KOL Meetings Focused On BNC210 And The Treatment Of PTSD In New York And London
Dec 19, 2017: Neurodyn Appoints Anthony J. Giovinazzo as Director and Executive Chairman
Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs
Sep 01, 2017: Bionomics BNC210 to Feature at the 30th ECNP Congress
Aug 21, 2017: Bionomics & MSD 5th Annual Neuroscience Symposium in October
Jul 21, 2017: Bionomics Presents at 13th Annual Bioshares Biotech Summit
Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
May 18, 2017: Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention
Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment
Jan 09, 2017: Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase
Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder
Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP
Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bionomics Ltd, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CoMentis Inc, H2 2018
Pipeline by Epigen Biosciences Inc, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Neuro Bio Ltd, H2 2018
Pipeline by NeuroDerm Ltd, H2 2018
Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018
Pipeline by Vanda Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Vinpocetine Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 135
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vinpocetine Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 128
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • Global Bone Morphogenetic Protein (BMP) 2 Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 117
    Bone morphogenetic proteins (BMPs) are naturally occurring proteins found in the human body. This family of proteins is involved in a myriad of cellular responses. Certain BMPs are osteoinductive—one of the three main categories of bone grafts—and play an active role in bone formation and maintenance. Scope of the Report: This report focuses on the Bone Morphogenetic Protein (BMP) 2 in global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Bone Morphogenetic Protein (BMP) 2 Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 115
    Bone morphogenetic proteins (BMPs) are naturally occurring proteins found in the human body. This family of proteins is involved in a myriad of cellular responses. Certain BMPs are osteoinductive—one of the three main categories of bone grafts—and play an active role in bone formation and maintenance. Scope of the Report: This report focuses on the Bone Morphogenetic Protein (BMP) 2 in global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • Global Bacillus Coagulans Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 137
    Bacillus Coagulans is a lactic acid-forming bacterial species within the genus Bacillus. The organism was first isolated and described as Bacillus Coagulans in 1915 by B.W. Hammer at the Iowa Agricultural Experiment Station as a cause of an outbreak of coagulation in evaporated milk packed by an Iowa condensary. Separately isolated in 1935 and described as Lactobacillus sporogenes in the fifth edition of Bergey's Manual, it exhibits characteristics typical of both genera Lactobacillus and Bacill......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Bacillus Coagulans Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 133
    Bacillus Coagulans is a lactic acid-forming bacterial species within the genus Bacillus. The organism was first isolated and described as Bacillus Coagulans in 1915 by B.W. Hammer at the Iowa Agricultural Experiment Station as a cause of an outbreak of coagulation in evaporated milk packed by an Iowa condensary. Separately isolated in 1935 and described as Lactobacillus sporogenes in the fifth edition of Bergey's Manual, it exhibits characteristics typical of both genera Lactobacillus and Bacill......
  • Global Pulmonary Drugs Market Research Report 2018
    Published: 16-Jul-2018        Price: US 2900 Onwards        Pages: 99
    This report studies the global Pulmonary Drugs market status and forecast, categorizes the global Pulmonary Drugs market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Pulmonary Drugs market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The ......
  • Global Hemostatic Agents Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Jul-2018        Price: US 3480 Onwards        Pages: 146
    Hemostatic agents are used as an adjunct or alternative to standard suturing techniques to control bleeding or for wound closure. Scope of the Report: This report focuses on the Hemostatic Agents in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Hemostatic Agents is expected to grow at a CAGR o......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Hemostatic Agents Market 2018, Forecast to 2023
    Published: 16-Jul-2018        Price: US 4880 Onwards        Pages: 154
    Hemostatic agents are used as an adjunct or alternative to standard suturing techniques to control bleeding or for wound closure. Scope of the Report: This report focuses on the Hemostatic Agents in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Hemostatic Agents is expected to grow at a CAGR o......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs